Our findings are in agreement with the data collected from 33 tumor expression datasets and genome set enrichment analysis (GSEA), which concluded that high KRAS expression levels have been observed among advanced clinical stages of various cancer types36. The gene discussed is KRAS; the disease is neoplasm.